Alembic Pharmaceuticals Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
Alembic Pharmaceuticals has a total shareholder equity of ₹48.2B and total debt of ₹5.1B, which brings its debt-to-equity ratio to 10.7%. Its total assets and total liabilities are ₹64.5B and ₹16.3B respectively. Alembic Pharmaceuticals's EBIT is ₹7.0B making its interest coverage ratio 13.2. It has cash and short-term investments of ₹1.2B.
Anahtar bilgiler
10.7%
Borç/özkaynak oranı
₹5.13b
Borç
| Faiz karşılama oranı | 13.2x |
| Nakit | ₹1.20b |
| Eşitlik | ₹48.18b |
| Toplam yükümlülükler | ₹16.27b |
| Toplam varlıklar | ₹64.46b |
Son finansal sağlık güncellemeleri
Is Alembic Pharmaceuticals (NSE:APLLTD) Using Too Much Debt?
Sep 03
Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly
Jun 03Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Jan 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly
Sep 27Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly
Jun 09Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Feb 22Recent updates
Alembic Pharmaceuticals Limited's (NSE:APLLTD) Intrinsic Value Is Potentially 17% Below Its Share Price
Sep 25Is Alembic Pharmaceuticals (NSE:APLLTD) Using Too Much Debt?
Sep 03Alembic Pharmaceuticals Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 13Market Participants Recognise Alembic Pharmaceuticals Limited's (NSE:APLLTD) Earnings Pushing Shares 25% Higher
Jul 20Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Rather Sparingly
Jun 03Does This Valuation Of Alembic Pharmaceuticals Limited (NSE:APLLTD) Imply Investors Are Overpaying?
May 11Results: Alembic Pharmaceuticals Limited Exceeded Expectations And The Consensus Has Updated Its Estimates
Feb 08Subdued Growth No Barrier To Alembic Pharmaceuticals Limited (NSE:APLLTD) With Shares Advancing 25%
Jan 21Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Jan 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Can Manage Its Debt Responsibly
Sep 27Alembic Pharmaceuticals (NSE:APLLTD) Seems To Use Debt Quite Sensibly
Jun 09A Look At The Fair Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)
Apr 13Is Alembic Pharmaceuticals (NSE:APLLTD) A Risky Investment?
Feb 22Alembic Pharmaceuticals Limited (NSE:APLLTD) Shares Could Be 21% Below Their Intrinsic Value Estimate
Jan 04We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Alembic Pharmaceuticals Limited's (NSE:APLLTD) CEO For Now
Nov 05Here's Why Alembic Pharmaceuticals (NSE:APLLTD) Has A Meaningful Debt Burden
Aug 10Estimating The Intrinsic Value Of Alembic Pharmaceuticals Limited (NSE:APLLTD)
Jul 20We Think Alembic Pharmaceuticals (NSE:APLLTD) Is Taking Some Risk With Its Debt
May 05Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: APLLTD's short term assets (₹30.8B) exceed its short term liabilities (₹14.6B).
Uzun Vadeli Yükümlülükler: APLLTD's short term assets (₹30.8B) exceed its long term liabilities (₹1.7B).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: APLLTD's net debt to equity ratio (8.2%) is considered satisfactory.
Borcun Azaltılması: APLLTD's debt to equity ratio has reduced from 41.5% to 10.7% over the past 5 years.
Borç Kapsamı: APLLTD's debt is well covered by operating cash flow (156.5%).
Faiz Kapsamı: APLLTD's interest payments on its debt are well covered by EBIT (13.2x coverage).